0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > Chemotherapy

Buy Now

Cancer Chemoprevention - Volume 2: Strategies for Cancer Chemoprevention (Mixed media product, 2005 ed.) Loot Price: R6,047
Discovery Miles 60 470
Cancer Chemoprevention - Volume 2: Strategies for Cancer Chemoprevention (Mixed media product, 2005 ed.): Gary J. Kelloff,...

Cancer Chemoprevention - Volume 2: Strategies for Cancer Chemoprevention (Mixed media product, 2005 ed.)

Gary J. Kelloff, Ernest T. Hawk, Caroline C. Sigman

Series: Cancer Drug Discovery and Development

 (sign in to rate)
Loot Price R6,047 Discovery Miles 60 470 | Repayment Terms: R567 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

Donate to Gift Of The Givers

Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated genes, and imaging of immediate impact on successful chemopreventive drug tissue architecture and molecular and cellular function is development-those that measure the risk of developing increasing our understanding of carcinogenesis and cancer invasive life-threatening disease, and those whose mo- progression. This knowledge is moving the focus of cancer lation can "reasonably predict" clinical benefit and, therapeutics, including cancer preventive treatments, to therefore, serve as surrogate endpoints for later-occurring drugs that take advantage of cellular control mechanisms clinical disease. Thus far, the biomarker that best measures to selectively suppress cancer progression. these two phenomena is intraepithelial neoplasia (IEN) Carcinogenesis is now visualized as a multifocal, because it is a near obligate precursor to cancer.

General

Imprint: HumanaPress
Country of origin: United States
Series: Cancer Drug Discovery and Development
Release date: February 2005
First published: 2005
Editors: Gary J. Kelloff • Ernest T. Hawk • Caroline C. Sigman
Dimensions: 279 x 210 x 36mm (L x W x T)
Format: Mixed media product
Pages: 543
Edition: 2005 ed.
ISBN-13: 978-1-58829-077-9
Categories: Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > Chemotherapy
LSN: 1-58829-077-8
Barcode: 9781588290779

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners